Neovasc Medical Ltd.
This article was originally published in Start Up
Executive Summary
Neovasc Medical intends to provide a solution for the millions of patients that can't benefit from bypass, PCIs and other traditional revascularization techniques. It has developed a minimally invasive procedure in which a stent inserted percutaneously into the coronary sinus partially restricts the flow of blood exiting into the arteries. The blood flows backwards into the heart, retroperfusing the tissue and reducing symptoms of ischemia.
You may also be interested in...
Start-Up Previews (03/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: Do-It-Yourself Dermatology, features profiles of Therative and Xthetix. Plus these Start-Ups Across Health Care: iCardiac Technologies, Jenken Biosciences, Neovasc Medical, and Syntaxin.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.